In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss advancement in Alzheimer’s testing and practical uses of artificial intelligence (AI) in healthcare. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories’ chief digital innovation officer, to explore the evolving role of data in research and development.

• Innovative Alzheimer’s test gets FDA clearance (00:33): Dr. Morice shares how a strategic collaboration is enabling Mayo Clinic Laboratories to offer a newly FDA-cleared blood test for Alzheimer’s disease for adults with cognitive symptoms as young as 40.
• AI helping diagnose rare diseases (03:37): Dr. Pritt and Dr. Morice reflect on a recent article highlighting how AI is helping clinicians identify rare diseases.
• Data use in research and development (08:16): Dr. Garcia discusses how data, AI, and cross-disciplinary collaboration are advancing research and innovation in laboratory medicine.

Note: Information in this post was accurate at the time of its posting.

Resources

• C2N Diagnostics: FDA clears C2N Diagnostics’ PrecivityAD2® —First Alzheimer’s blood test for adults with cognitive symptoms as young as 40
• Wall Street Journal: AI is helping patients solve medical mysteries
• Answers From the Lab: Digital Advances: What's Next for Clinical Diagnostics?
• Answers From the Lab: Accelerating Research and Development With BioPharma Diagnostics